SCHEDULE: ATW Master Fund V Discloses 9.9% Stake in ENDRA Life Sciences

ATW Master Fund V LP and its affiliates have disclosed a 9.9% beneficial ownership stake in ENDRA Life Sciences Inc., totaling 116,024 common shares.

Summary

• ATW Master Fund V LP, along with ATW Partners Opportunities Management, LLC, Kerry Propper, and Antonio Ruiz-Gimenez, reported beneficial ownership of 116,024 common shares of ENDRA Life Sciences Inc.
• This represents 9.9% of the outstanding common stock, based on 1,166,441 shares outstanding as of October 16, 2025.
• The ownership includes shares held directly by ATW Master Fund V LP, as well as certain warrants and prefunded warrants, all subject to a 9.99% beneficial ownership blocker.
• The reporting persons share voting and dispositive power over these 116,024 shares.
• The filing certifies that the securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.9% passive stake by an institutional investor like ATW Master Fund V LP is generally a positive signal, indicating confidence in ENDRA Life Sciences Inc. The presence of warrants and prefunded warrants, even with a blocker, suggests potential for future upside if the investor chooses to increase their economic exposure.

Positives

• A significant institutional investor, ATW Master Fund V LP, has taken a substantial 9.9% stake in ENDRA Life Sciences Inc., indicating confidence in the company.
• The investment is passive, as certified by the reporting persons, suggesting a long-term investment horizon rather than an activist stance.

Risks

• The existence of a 9.99% beneficial ownership blocker on warrants and prefunded warrants limits the immediate ability for the investor to increase their stake beyond this threshold through conversion without further disclosure or potential regulatory implications.

Future Outlook

The filing does not provide any forward-looking statements or guidance from the company or the reporting persons regarding the issuer's future performance. It is a disclosure of current ownership.

Industry Context

This filing indicates that a significant institutional investor sees value in ENDRA Life Sciences Inc., a company likely operating in the life sciences or medical technology sector. Such an investment can be a positive signal to the market, potentially attracting further investor interest in the company and its industry peers.

Comparison to Industry Standards

• A 9.9% stake is a substantial passive investment, often seen as a strong vote of confidence from an institutional investor.
• The use of a 9.99% blocker is a common strategy for institutional investors to maintain a significant stake without triggering certain regulatory thresholds (e.g., 10% ownership which can lead to insider trading rules under Section 16 of the Exchange Act) or activist investor classifications.
• This level of ownership is comparable to other institutional investments in small-cap or emerging life sciences companies where strategic positioning is key.

Stakeholder Impact

• Shareholders: May view the significant institutional investment as a positive indicator, potentially boosting confidence and share price.
• Company Management: Could see this as validation of their strategy and potentially a stable, long-term shareholder.

Key Dates

Recommendation

The disclosure of a 9.9% beneficial ownership by ATW Master Fund V LP, a reputable institutional investor, signals a vote of confidence in ENDRA Life Sciences Inc. While this filing does not provide operational or financial performance data, the substantial passive stake suggests a positive long-term view from a sophisticated investor. Existing shareholders may consider holding their positions based on this institutional endorsement, but further analysis of the company's fundamentals is required for a more definitive investment decision.

Keywords

ENDRA Life Sciences, ATW Master Fund V, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Equity Stake, Warrants, Prefunded Warrants, Shareholder Disclosure